Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cervical cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 94.00 | |
5 mg | In stock | $ 263.00 | |
10 mg | In stock | $ 416.00 | |
25 mg | In stock | $ 692.00 | |
50 mg | In stock | $ 985.00 | |
100 mg | In stock | $ 1,330.00 | |
500 mg | In stock | $ 2,660.00 |
Description | TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cervical cancer. |
Targets&IC50 | JAK2:11.2 μM |
Molecular Weight | 510.65 |
Formula | C26H34N6O3S |
CAS No. | 936091-56-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 9.0 mg/mL (17.6 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TG-89 936091-56-4 Angiogenesis Apoptosis Chromatin/Epigenetic JAK/STAT signaling Stem Cells Tyrosine Kinase/Adaptors FLT c-RET JAK TG 89 TG89 inhibitor inhibit